Articles tagged with Lung Cancer
The KEYNOTE-024 trial found that pembrolizumab significantly improved progression-free and overall survival in patients with advanced non-small-cell lung cancer. Patients treated with pembrolizumab had a median overall survival of 26.3 months compared to 14.2 months for those on chemotherapy.
A survey of European patients with lung cancer revealed that many were unaware of or had never heard of clinical trials. Despite positive experiences by over 50%, respondents identified difficulties in accessing trials, including language barriers, limited information, and disparities across Europe.
The Impower131 Trial found that atezolizumab + chemotherapy improved overall survival by 3.9 months compared to chemotherapy alone, particularly among patients with high PD-L1 expression. Treatment-related side effects were common but manageable in both arms.
A nurse-led follow-up service has improved patient care for those with early-stage lung cancer by increasing clinic capacity, reducing waiting times, and ensuring continuity of care. The service also promotes junior medical training and is well-received by patients and the multidisciplinary team.
Patients taking nivolumab experience a significant five-fold increase in overall survival, with five-year rates of 13.4% compared to docetaxel's 2.6%. Long-term benefits and improved progression-free survival have been observed with nivolumab treatment.
A new trial found that video-assisted thoracic surgery (VATS) significantly reduces in-hospital complications and shortens hospital stays compared to open surgery for early-stage lung cancer patients. VATS, a minimally invasive technique, showed improved outcomes without compromising oncologic results.
A European lung cancer screening model outperformed a US model in detecting cancers, with 99% of cancers found using the European method compared to 77%. The study found that the model detected more cancers among high-risk patients and had a higher accuracy rate.
The bioMILD trial demonstrated that a blood microRNA assay, combined with low-dose CT screening, is safe and effective in enhancing lung cancer prevention. Preliminary analysis showed a significantly higher lung cancer incidence and overall mortality in subjects with positive LDCT and/or miRNA at baseline.
A blood test has been shown to detect lung cancer earlier, identifying 32% of cases with a high specificity of 90%. This could lead to reduced late-stage presentations and improved survival rates for patients.
The NLMT trial tests eight targeted therapies tailored to specific molecular changes in cancer cells. Researchers found promising responses with single-agent targeted therapy, particularly in oncogene-addicted NSCLC, and identified potential biomarkers for further research.
A Scottish study shows that combining an autoantibody test with CT imaging can significantly decrease late-stage lung cancer diagnoses and potentially lower lung cancer-specific mortality. The EarlyCDT-Lung Test identifies high-risk individuals, allowing for earlier interventions.
The MYSTIC trial found that patients with STK11 or KEAP1 gene mutations in metastatic non-small cell lung cancer experienced poorer overall survival compared to those without these mutations. Additionally, patients with ARID1A mutations in the durvalumab + tremelimumab arm had longer median overall survival rates.
The bioMILD trial demonstrated that combining low-dose CT screening with a microRNA blood test reduces lung cancer mortality and incidence in high-risk individuals. The study found that participants with positive LDCT and/or miRNA at baseline had a significantly higher lung cancer incidence and overall mortality.
A Phase 1 study demonstrated early promising antitumor activity and few adverse side effects in patients with advanced non-small cell lung cancer harboring KRAS G12C mutation. The therapy, AMG 510, showed encouraging anti-tumor activity with no dose-limiting toxicities or adverse events leading to discontinuation.
Research presented at the IASLC 2019 World Conference on Lung Cancer found that combining nivolumab with ipilimumab showed improved efficacy in patients with advanced non-small cell lung cancer (NSCLC), particularly those with high TMB or higher tumor PD-L1 expression. The safety profile of this combination therapy was also consistent ...
Researchers found no significant correlation between tumor mutational burden and response rates, progression-free survival, or overall survival in patients treated with pembrolizumab plus carboplatin and pemetrexed. High objective response rates were observed in both TMB low and high subgroups.
The MYSTIC trial found that patients with STK11 or KEAP1 mutations had poorer outcomes to anti-PD-L1 and anti-CTLA-4 immunotherapies compared to those without these mutations. ARID1A mutations were associated with improved survival in the durvalumab + tremelimumab arm.
Researchers studied the relationship between tumor mutational burden and response to immunotherapy with pembrolizumab. The study found that high or low TMB levels did not significantly impact overall survival, progression-free survival, or objective response rates for patients with metastatic nonsquamous non-small cell lung cancer.
Cancer patients who continue smoking after diagnosis have a higher mortality rate and increased risk for second cancer development. The IASLC Declaration recommends screening all cancer patients for tobacco use and advising on tobacco cessation.
Researchers at H. Lee Moffitt Cancer Center describe a promising new treatment combination for patients with non-small cell lung cancer, showing preliminary efficacy and improved tolerance compared to standard treatments.
Researchers found a gene mutation in nearly half of dogs with lung cancer that could be treated with the same drug used for human breast cancer. A clinical trial is planned for dogs with naturally occurring lung cancer and the HER2 mutation.
Researchers at Moffitt Cancer Center have discovered a new treatment approach that may help nearly a third of lung cancer patients with KRAS mutations. The combination therapy targets the MEK kinase and enhances anti-tumor immunity through cytokines TNFα and IFNγ.
Researchers found that combining therapies reduced tumor relapse and side effects in mouse models of kinase mutated breast cancer. The study suggests using two therapies together, rather than one after the other, to improve treatment outcomes.
Researchers combine checkpoint blockade therapy with stem cell transplantation to boost efficacy in non-Hodgkin's lymphomas and melanoma. The approach increases cancer-killing immune response tenfold, allowing it to be effective for previously treatment-resistant cancers.
Researchers at Mayo Clinic have identified two distinct pathways for lung adenocarcinoma development, which can inform treatment strategies and predict patient response. The study's findings suggest that targeting specific pathways may provide alternative treatment options for patients with limited response to traditional therapies.
Scientists have developed a highly sensitive 'sniff-cam' that can detect low levels of disease biomarkers in breath, including diabetes, lung cancer, and Parkinson's disease. The device uses an ultraviolet ring light, filters, and a camera to measure volatile organic compounds (VOCs) in the breath.
Retinitis pigmentosa (RP) is caused by the starvation of photoreceptors due to disrupted glucose transport. Research led by UofL's Douglas C. Dean and Wei Wang found similar metabolic changes in lung cancer.
Researchers have discovered that two enzymes, SIK1 and SIK3, play a critical role in driving tumor growth in non-small-cell lung cancer by promoting inflammation. The findings highlight a potential new target for therapies and could lead to improved treatment options for patients with this deadly form of lung cancer.
A new AI tool developed by Dana-Farber Cancer Institute can extract high-value cancer outcomes from unstructured radiology reports with comparable accuracy to human reviewers. The tool, trained on over 14,000 imaging reports, was able to replicate human assessments of disease-free survival and progression-free survival.
A new study published in Science Advances reveals that a cellular switch called CREB plays a key role in directing tumor growth in non-small-cell lung cancer. Researchers found that blocking this switch could have therapeutic benefits for patients with this deadly type of cancer.
A new AI tool, CXR-risk, analyzes chest X-ray images to predict health and mortality, providing independent information that surpasses radiologists' readings. The study found that CXR-risk identified people at high risk for future heart attack, lung cancer, or death with accuracy.
A Northwestern University study found that many deadliest cancers, such as colon, lung, and liver cancer, receive significantly less nonprofit research funding than breast cancer, leukemia, and other well-funded types. This underfunding could impact research, drug development, and FDA approvals for these life-altering diseases.
Researchers at Massachusetts General Hospital have identified markers that can distinguish between major subtypes of lung cancer and accurately predict lung cancer stage. The study's findings could help physicians decide whether an individual patient with lung cancer benefits from standard treatment or needs more aggressive therapy.
Radiotherapy patients experiencing hurricane disasters had significantly worse overall survival rates than those completing treatment in normal circumstances. Longer disaster declarations were associated with increasingly worse survival outcomes.
Researchers found adding pembrolizumab to definitive treatment increased overall average PFS by 19.1 months, compared to 6.6 months in historical averages. The study showed the treatment did not lead to new safety issues or decreased patient quality of life.
Research reveals that epigenetic regulation-mediated metabolic reprogramming enables lung cancer cells to adapt to and resist targeted therapies. BCAT1 upregulation allows for glutathione generation, eliminating oxidative stress and promoting drug resistance.
A follow-up study reaffirms the effectiveness of low-dose computed tomography (LDCT) in reducing lung cancer mortality. The research found that LDCT can prevent lung cancer deaths or at least delay them for more than a decade, with only 303 patients needed to be screened to prevent one death.
A study suggests that current USPSTF guidelines for African American smokers may lead to fewer screenings due to lower smoking pack-year history. Lowering the pack-year requirement and minimum age criterion could increase eligible African Americans for lung cancer screening.
The study found that African Americans are excluded from CT scans at a rate of 68%, compared to 32% of whites, due to conservative guidelines. Modifying the minimum smoking history and age thresholds could increase eligibility and reduce disparities.
Researchers have discovered how lung cancer cells metastasize by stabilizing protein BACH1, which stimulates glucose metabolism and boosts cancer cell spreading. The studies published in Cell provide a crucial new piece of the oncological puzzle and offer a potential explanation for the Warburg effect.
A new risk prediction model using clinical and radiological features can stratify individuals with lung nodules as having high or low risk of developing lung cancer. The model, which combines variables such as age, smoking history, and nodule characteristics, showed a sensitivity and specificity of 73% and 81%, respectively.
A new study reveals that high antioxidant levels may accelerate lung cancer spread, contradicting the long-held notion that antioxidants like vitamin E prevent cancer. The research highlights a complex interplay between protein BACH1, NRF2, and heme-driven oxidative stress in facilitating cancer cell migration.
Research teams discovered that uridine diphosphate glucose accelerates SNAI1 mRNA decay, impairing lung cancer metastasis. Lower UDP-glucose levels are associated with higher metastasis and recurrence rates in lung cancer.
Scientists discover that UDP-glucose accelerates SNAI1 mRNA decay, impairing lung cancer metastasis. The study also uncovers how UDP-glucose converts to UDP-glucuronic acid, enhancing SNAI1 mRNA stability and promoting tumor cell migration.
The Hollings Cancer Center has received a $3 million grant from the National Cancer Institute to continue its research on a novel immunotherapy combination for treating lung cancer. The team, led by Mark Rubinstein and John Wrangle, aims to understand why some patients respond better to this treatment than others.
Researchers have trained beagles to identify lung cancer by scent with 97% accuracy, offering a potential solution for earlier detection. The dogs' abilities may lead to the development of an over-the-counter screening product, similar to a pregnancy test.
Seven early-career scholars are awarded four-year grants to advance their research on reprogramming tumor-associated immune cells, mutant proteins in lung cancer, and treating acute myeloid leukemia.
A study suggests that the current UK legislation favoring cancer patients for early release on compassionate grounds may be discriminatory. The data analysis found that only 48 out of 845 recorded deaths from natural causes in prison were successful, with all six prisoners having cancer.
A retrospective study of 748 NSCLC patients found that the average radiation dose delivered to the heart was associated with an increased risk of major adverse cardiovascular events and death. The team's findings highlight the need for more stringent avoidance of high cardiac radiotherapy doses and collaboration with cardiologists to m...
The combination immunotherapy of nivolumab and ipilimumab met the primary endpoint of the NEOSTAR trial with a 33% overall major pathologic response rate in early-stage lung cancer patients. The treatment was also shown to be effective in reducing tumor viability, with six out of 21 patients achieving a complete pathological response.
A new essay published in Annals of Internal Medicine argues that physicians often have to make difficult decisions when faced with extreme political pressures. The author shares a personal story about caring for a pregnant woman who was forced to carry a baby without a brain, highlighting the need for compassion over 'choice' in patien...
The NRG-LU001 trial showed that metformin was well-tolerated by patients with locally advanced non-small cell lung cancer, but did not improve progression-free survival or overall survival rates. The study found better-than-expected PFS and OS rates in both treatment arms.
Researchers found that catastrophic genome rearrangements can occur as early as childhood and lead to lung cancer decades later. Gene fusions in non-smokers mostly occur early on, sometimes as early as childhood or adolescence, and are often dormant for several decades before progressing into cancer.
Researchers from Stand Up To Cancer will discuss their work on advancing immunotherapy for pediatric brain tumors, genome-wide cell-free DNA fragmentation profiling for early cancer detection, and personalized consolidation immunotherapy in localized non-small cell lung cancer. The findings highlight promising approaches to screening, ...
A new study presented at ASCO 2019 shows that brigatinib is effective in patients who have received another next-generation ALK inhibitor. The 40-50 percent response rate suggests that brigatinib may be a useful treatment option for these patients. Detailed molecular analyses will help determine the characteristics of patients sensitiv...
A virtual clinical trial using real-world data found entrectinib to be more effective than crizotinib in treating ROS1+ lung cancer. Patients on entrectinib stayed on treatment longer and had a 44% increased chance of cancer recurrence compared to those on crizotinib.
A new study from the University of British Columbia found that steroid inhalers can lower lung cancer risk in COPD patients. The research, published in European Respiratory Journal, analyzed data from 39,676 adults with COPD and found a 25-30% reduction in lung cancer risk among those using steroids.
Smokers of unfiltered cigarettes face a significantly higher risk of dying from lung cancer and all causes than those who smoke filtered cigarettes. Researchers found that light or ultralight cigarettes do not offer any lung cancer death reduction benefits, but smokers may be less likely to quit.
Research at ATS 2019 reveals that smokers with severe lung function limitation are more likely to die from respiratory causes. In contrast, smokers with mild impairment face a higher risk of heart disease and lung cancer.
A new AI system has been developed that can detect lung cancer with high accuracy, potentially leading to earlier treatment. The system uses deep learning to analyze low-dose chest computed tomography (LDCT) scans and performs better than human radiologists in detecting malignant nodules.